• Investors may be wondering whether Indivior Pharmaceuticals at US$37.66 still offers value after a strong run, or if most of the opportunity is already priced in.
• The stock has returned 13.3% over the last 7 days, 22.9% over 30 days, 5.4% year to date, 214.4% over 1 year, 88.0% over 3 years and 250.3% over 5 years. This raises questions about how its current price lines up with underlying value.
• Recent coverage has focused on Indivior Pharmaceuticals as a US-listed pharmaceuticals business with a rapidly rising share price. This has drawn attention to how its market value compares with fundamentals and peers. Investors are now looking more closely at what standard metrics like P/E and discounted cash flow say about the stock.
• On Simply Wall St's 6-point valuation check, Indivior Pharmaceuticals scores 5 out of 6. The next step is a closer look at the main valuation approaches used and how they compare with a more complete way of thinking about value that will be covered at the end of this article.

Approach 1: Indivior Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a business could be worth today by projecting its future cash flows and then discounting those back to a present value. It is essentially asking what all the expected future cash that could flow to shareholders is worth in today’s dollars.

For Indivior Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is a loss of $170.4 million, while analysts and internal estimates project free cash flow reaching $536.5 million by 2030. For the period 2026 to 2035, Simply Wall St uses a mix of analyst estimates for the earlier years and extrapolated growth rates for the later years to build a ten year cash flow path in dollars.

Discounting these projected cash flows produces an estimated intrinsic value of $109.43 per share. Compared with the current share price of $37.66, this implies the stock is 65.6% undervalued based on this DCF model.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Indivior Pharmaceuticals is undervalued by 65.6%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Indivior Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to link what you pay for each share to the earnings that support that price. It helps you see how many dollars investors are currently willing to pay for each dollar of earnings.

What counts as a “normal” P/E depends on how fast earnings are expected to grow and how risky those earnings are. Higher expected growth and lower perceived risk usually justify a higher P/E, while slower growth or higher risk point to a lower, more cautious multiple.

Indivior Pharmaceuticals currently trades on a P/E of 18.2x, compared with the Pharmaceuticals industry average of 16.1x and a peer average of 57.0x. Simply Wall St’s Fair Ratio of 19.6x is a proprietary estimate of what the P/E might be given factors such as earnings growth, profit margins, industry, market cap and key risks. This tailored Fair Ratio can be more informative than a simple comparison with peers or the industry, because it adjusts for company specific characteristics rather than relying on broad group averages.

Set against the Fair Ratio of 19.6x, the current P/E of 18.2x indicates that Indivior Pharmaceuticals is trading below this metric-specific valuation benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Indivior Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring together your view of Indivior Pharmaceuticals, your assumptions for future revenue, earnings and margins, and a resulting fair value in one simple story that lives on Simply Wall St’s Community page. This helps you compare that fair value against the current price when deciding whether to buy or sell. It automatically refreshes as new news or earnings arrive and can look very different from one investor to the next. For example, one user might build a bullish Indivior view around a fair value of US$50.00, while another might anchor on a more cautious fair value close to US$37.86.

Do you think there's more to the story for Indivior Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.